<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04587492</url>
  </required_header>
  <id_info>
    <org_study_id>0120-305/2018/11</org_study_id>
    <nct_id>NCT04587492</nct_id>
  </id_info>
  <brief_title>Metabolomics of Children With SMA</brief_title>
  <official_title>Metabolome of Children With Spinal Muscular Atrophy Treated With Nusinersen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the proposed project is to evaluate whether the metabolome of patients with spinal&#xD;
      muscular atrophy (SMA) before the initiation of treatment with nusinersen differs from the&#xD;
      metabolome of healthy individuals and whether it changes 14 months after treatment with&#xD;
      nusinersen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal muscular atrophy (SMA) is a severe, debilitating disease and is an important source of&#xD;
      morbidity and mortality of children. Novel disease modifying therapies can alter the natural&#xD;
      course of the disease. However, many aspects of their action remain unknown. Metabolomics is&#xD;
      the large-scale study of metabolites, within cells, biofluids, tissues or organisms.&#xD;
      Collectively, these small molecules and their interactions within a biological system are&#xD;
      known as the metabolome.&#xD;
&#xD;
      The aim of this study is to evaluate whether the metabolome of patients with SMA before the&#xD;
      initiation of disease modifying therapy with nusinersen differs from the metabolome of&#xD;
      healthy individuals. Next, we would like to asses whether tretament with nusinersen alters&#xD;
      the metabolome of patients with SMA. Utilizing metabolomics, we would like to assess whether&#xD;
      we can identify parameters reflecting the state of the disease in a particular patient, and&#xD;
      parameters with diagnostic and/or prognostic value. Using metabolomics, we will aim to&#xD;
      identify SMA patients that will positively respond to gene therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolomic difference from healthy children</measure>
    <time_frame>Beginning of study</time_frame>
    <description>Metabolomic difference between children with SMA and healthy children</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolomic change before and after treatment</measure>
    <time_frame>At least 14 months of treatment</time_frame>
    <description>Metabolomic change in children with SMA before and after treatment with nusinersen</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Children with SMA</arm_group_label>
    <description>All children with SMA are eligible for the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nusinersen</intervention_name>
    <description>Treatment with nusinersen</description>
    <arm_group_label>Children with SMA</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cerebrospinal fluid, serum, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children with genetically diagnosed SMA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genetically confirmed SMA&#xD;
&#xD;
          -  Age up to 21 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biotechnical faculty</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Damjan Osredkar</investigator_full_name>
    <investigator_title>Associate Professor in Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Spinal Muscular Atrophy, nusinersen, metabolome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

